Swedbank Ab Allogene Therapeutics, Inc. Transaction History

Swedbank Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Dec 09, 2024	SELL	$2.28 - $3.5 $492,103 - $755,422	-215,835 Reduced 23.57%	700,000 $2.25 Million
Q3 2023 Dec 09, 2024	SELL	$3.17 - $5.96 $266,803 - $501,623	-84,165 Reduced 8.42%	915,835 $2.9 Million
Q1 2023 Dec 09, 2024	BUY	$4.92 - $8.21 $2.8 Million - $4.66 Million	568,184 Added 131.58%	1,000,000 $4.94 Million
Q4 2022 Dec 09, 2024	BUY	$5.62 - $11.11 $1.83 Million - $3.63 Million	326,316 Added 309.3%	431,816 $2.72 Million
Q3 2022 Dec 09, 2024	BUY	$10.32 - $17.28 $1.09 Million - $1.82 Million	105,500 New	105,500 $1.14 Million

165

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $279M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Swedbank Ab, based on Form 13F filings with the SEC.

Stay updated on Swedbank Ab with notifications on news.